Menu
Search
|

Menu

Close
X

Halozyme Therapeutics Inc HALO.OQ (NASDAQ Stock Exchange Global Select Market)

17.70 USD
-0.39 (-2.16%)
As of 1:47 PM EDT
chart
Previous Close 18.09
Open 18.01
Volume 97,138
3m Avg Volume 304,951
Today’s High 18.06
Today’s Low 17.38
52 Week High 21.47
52 Week Low 11.43
Shares Outstanding (mil) 143.97
Market Capitalization (mil) 2,604.34
Forward P/E 34.63
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.67 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
31
FY17
317
FY16
147
FY15
135
EPS (USD)
FY18
-0.192
FY17
0.459
FY16
-0.805
FY15
-0.257
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
34.63
34.14
Price to Sales (TTM)
vs sector
8.19
8.17
Price to Book (MRQ)
vs sector
9.82
4.30
Price to Cash Flow (TTM)
vs sector
29.72
22.70
Total Debt to Equity (MRQ)
vs sector
69.85
17.55
LT Debt to Equity (MRQ)
vs sector
38.74
13.12
Return on Investment (TTM)
vs sector
31.59
13.10
Return on Equity (TTM)
vs sector
82.79
15.09

EXECUTIVE LEADERSHIP

Connie Matsui
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Helen Torley
President, Chief Executive Officer, Director, Since 2014
Salary: $671,000.00
Bonus: $699,115.00
Laurie Stelzer
Chief Financial Officer, Senior Vice President, Since 2015
Salary: $452,000.00
Bonus: $282,563.00
Harry Leonhardt
Senior Vice President, Chief Compliance Officer, General Counsel, Since 2015
Salary: $425,000.00
Bonus: $242,582.00
Athena Countouriotis
Senior Vice President, Chief Medical Officer, Since 2015
Salary: $236,493.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11388 Sorrento Valley Rd
SAN DIEGO   CA   92121-1345

Phone: +1858.7948889

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

SPONSORED STORIES